Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Immunocore Holdings Q3 2026 Results: Net Loss of $14.2M, Loss Widens

For the nine months ended September 30, 2026, Immunocore reported total revenue of $324.8 million, a 10% increase over the prior year, and a significantly narrowed net loss of $2.1 million compared to $5.5 million in 2025. The company maintained a strong liquidity position with $901.3 million in cash, cash equivalents, and marketable securities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue102.2103.7
Profit before tax-14.10.3
Net income-14.2-0.2
EPS (diluted, $ a share)$-0.28$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-1.4%
Operating margin-13.3%
Source

10-Q filed with the SEC, NASDAQ: IMCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Immunocore Holdings plc: key numbers

Share price
$28.88Close, Nov 16
Market cap
$1.49B
Shares outstanding
51.68MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Immunocore Holdings plc

All →
9:01 AM ET 8-K
Financial Results

Immunocore Holdings Financial Results

Immunocore reported Q3 2026 financial results with KIMMTRAK net revenues of $102.2 million and a net loss of $14.2 million. The company highlighted the completion of target enrollment for its Phase 3 TEBE-AM trial in cutaneous melanoma and the first patient dosed in its autoimmune program for type 1 diabetes.

Term
Q3 2026

“Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients.”

Bahija Jallal, CEO of Immunocore

“Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes.”

Bahija Jallal, CEO of Immunocore
7:15 AM ET 8-K
Business Update

Immunocore Holdings Business Update

Immunocore has achieved its target enrollment of 540 patients in the Phase 3 TEBE-AM clinical trial evaluating tebentafusp (KIMMTRAK) for the treatment of advanced melanoma. The trial is a registrational study, and the company expects to report topline overall survival data as early as the end of 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.